1] Division of Oncology, Center for Applied Medical Research, University of Navarra, 31080 Pamplona, Spain [2] Department of Histology and Pathology, University of Navarra, 31080 Pamplona, Spain.
1] Division of Oncology, Center for Applied Medical Research, University of Navarra, 31080 Pamplona, Spain [2] Department of Biochemistry and Genetics, University of Navarra, 31080 Pamplona, Spain.
Br J Cancer. 2014 Mar 18;110(6):1545-51. doi: 10.1038/bjc.2014.33. Epub 2014 Jan 30.
Transforming growth factor β-induced protein (TGFBI) is a secreted protein that mediates cell anchoring to the extracellular matrix. This protein is downregulated in lung cancer, and when overexpressed, contributes to apoptotic cell death. Using a small series of stage IV non-small cell lung cancer (NSCLC) patients, we previously suggested the usefulness of TGFBI as a prognostic and predictive factor in chemotherapy-treated late-stage NSCLC. In order to validate and extend these results, we broaden the analysis and studied TGFBI expression in a large series of samples obtained from stage I-IV NSCLC patients.
TGFBI expression was assessed by immunohistochemistry in 364 completely resected primary NSCLC samples: 242 adenocarcinomas (ADCs) and 122 squamous cell carcinomas (SCCs). Kaplan-Meier curves, log-rank tests and the Cox proportional hazards model were used to analyse the association between TGFBI expression and survival.
High TGFBI levels were associated with longer overall survival (OS, P<0.001) and progression-free survival (PFS, P<0.001) in SCC patients who received adjuvant platinium-based chemotherapy. Moreover, multivariate analysis demonstrated that high TGFBI expression is an independent predictor of better survival in patients (OS: P=0.030 and PFS: P=0.026).
TGFBI may be useful for the identification of a subset of NSCLC who may benefit from adjuvant therapy.
转化生长因子 β 诱导蛋白（TGFBI）是一种分泌蛋白，可介导细胞与细胞外基质的锚定。这种蛋白在肺癌中表达下调，当过度表达时，会导致细胞凋亡死亡。我们之前使用一小系列 IV 期非小细胞肺癌（NSCLC）患者的数据，提示 TGFBI 作为化疗治疗晚期 NSCLC 的预后和预测因子具有一定的临床价值。为了验证和扩展这些结果，我们扩大了分析范围，并在来自 I-IV 期 NSCLC 患者的大量样本中研究了 TGFBI 表达。
在 364 例完全切除的原发性 NSCLC 样本中，通过免疫组织化学评估 TGFBI 的表达：242 例腺癌（ADC）和 122 例鳞状细胞癌（SCC）。Kaplan-Meier 曲线、对数秩检验和 Cox 比例风险模型用于分析 TGFBI 表达与生存之间的关系。
在接受含铂辅助化疗的 SCC 患者中，高 TGFBI 水平与总生存期（OS，P<0.001）和无进展生存期（PFS，P<0.001）延长相关。此外，多变量分析表明，高 TGFBI 表达是患者生存的独立预测因素（OS：P=0.030，PFS：P=0.026）。
TGFBI 可能有助于识别可能从辅助治疗中获益的 NSCLC 亚组患者。
